MedTrace Logo

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

NCT00844103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2009-04-30

No results posted yet for this study

Summary

The purpose of this study is to determine how well tolerated and safe AZD8566 is when given over 10 days, at different dose levels. This study will also determine how AZD8566 is distributed around the body and how it leaves the body.

Conditions

  • Pharmacokinetics

Interventions

DRUG

AZD8566

10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee

DRUG

Placebo

10ml oral solution administered once a day over 10 days.

Sponsors & Collaborators

Principal Investigators

  • Emeline Ramos, MD · Clinical Pharmacology Unit

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00844103 on ClinicalTrials.gov